Concepts (86)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Plasminogen Activator Inhibitor 1 | 2 | 2021 | 58 | 1.490 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2022 | 1085 | 1.090 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 940 | 0.980 |
Why?
|
| Weight Loss | 3 | 2022 | 319 | 0.840 |
Why?
|
| Lipolysis | 1 | 2021 | 13 | 0.760 |
Why?
|
| Fatty Liver | 1 | 2021 | 97 | 0.720 |
Why?
|
| Dyslipidemias | 1 | 2021 | 98 | 0.700 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2017 | 3 | 0.600 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2017 | 20 | 0.590 |
Why?
|
| Insulin-Secreting Cells | 1 | 2016 | 41 | 0.530 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 93 | 0.530 |
Why?
|
| Body Weight | 2 | 2022 | 554 | 0.510 |
Why?
|
| Hospitals | 1 | 2017 | 265 | 0.490 |
Why?
|
| Insulin Resistance | 1 | 2016 | 241 | 0.480 |
Why?
|
| Blood Glucose | 1 | 2016 | 631 | 0.430 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.370 |
Why?
|
| Computer Simulation | 2 | 2014 | 706 | 0.340 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 689 | 0.320 |
Why?
|
| Models, Biological | 1 | 2012 | 981 | 0.310 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 2 | 2022 | 20 | 0.260 |
Why?
|
| Hypoglycemic Agents | 3 | 2022 | 362 | 0.250 |
Why?
|
| Mice | 3 | 2021 | 8474 | 0.220 |
Why?
|
| Insulins | 1 | 2022 | 5 | 0.220 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 17 | 0.210 |
Why?
|
| Hypoglycemia | 1 | 2022 | 72 | 0.200 |
Why?
|
| Cardiotonic Agents | 1 | 2022 | 71 | 0.200 |
Why?
|
| Metformin | 1 | 2022 | 63 | 0.200 |
Why?
|
| Mice, Obese | 1 | 2021 | 33 | 0.190 |
Why?
|
| Proprotein Convertase 9 | 1 | 2021 | 14 | 0.190 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 68 | 0.190 |
Why?
|
| Fibroblast Growth Factors | 1 | 2021 | 51 | 0.180 |
Why?
|
| Overweight | 1 | 2022 | 186 | 0.180 |
Why?
|
| Risk Factors | 2 | 2022 | 5731 | 0.170 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.170 |
Why?
|
| Animals | 5 | 2021 | 20881 | 0.170 |
Why?
|
| Humans | 9 | 2022 | 68618 | 0.150 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1033 | 0.150 |
Why?
|
| Algorithms | 2 | 2014 | 1196 | 0.150 |
Why?
|
| Male | 4 | 2021 | 37321 | 0.140 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 75 | 0.140 |
Why?
|
| Tamoxifen | 1 | 2016 | 62 | 0.130 |
Why?
|
| Codon, Terminator | 1 | 2015 | 6 | 0.130 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2673 | 0.130 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 79 | 0.120 |
Why?
|
| Obesity | 1 | 2022 | 1076 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 2358 | 0.120 |
Why?
|
| Feeding Behavior | 1 | 2016 | 224 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 2791 | 0.120 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 301 | 0.110 |
Why?
|
| Computer Graphics | 1 | 2014 | 37 | 0.110 |
Why?
|
| Insulin | 1 | 2016 | 619 | 0.110 |
Why?
|
| Gastric Inhibitory Polypeptide | 2 | 2022 | 6 | 0.110 |
Why?
|
| Proteins | 1 | 2015 | 474 | 0.100 |
Why?
|
| Hospitalization | 1 | 2017 | 978 | 0.100 |
Why?
|
| United States | 1 | 2022 | 7367 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2009 | 24 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 290 | 0.070 |
Why?
|
| Female | 2 | 2021 | 38074 | 0.070 |
Why?
|
| Glucagon-Like Peptides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Aged | 1 | 2017 | 14862 | 0.050 |
Why?
|
| Glucose | 1 | 2022 | 307 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1738 | 0.040 |
Why?
|
| Saccharomyces | 1 | 2015 | 6 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 37 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 56 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2015 | 44 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2015 | 80 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2015 | 123 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2015 | 362 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2014 | 55 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2015 | 173 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 333 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 7029 | 0.020 |
Why?
|
| NAV1.2 Voltage-Gated Sodium Channel | 1 | 2009 | 1 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2009 | 42 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 85 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2009 | 136 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 255 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 322 | 0.020 |
Why?
|
| Action Potentials | 1 | 2009 | 223 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 239 | 0.020 |
Why?
|
| Protein Binding | 1 | 2009 | 1027 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 2223 | 0.020 |
Why?
|
| Calcium | 1 | 2009 | 929 | 0.020 |
Why?
|
| Epilepsy | 1 | 2009 | 336 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 1213 | 0.010 |
Why?
|